Grafalon

Grafalon is a rabbit-derived anti‑T lymphocyte immunoglobulin for human use, supplied as a sterile solution for intravenous injection. The product contains polyclonal antibodies that target human T lymphocytes, leading to their depletion. It is marketed in the European Union as a prescription immunosuppressive agent and is administered under medical supervision. The preparation is provided in a single‑use vial and requires reconstitution according to the manufacturer's instructions before infusion.

Grafalon is employed as an immunosuppressive agent in clinical settings where T‑cell mediated immune responses need to be controlled.

- Prevention of acute rejection in organ transplantation (e.g., kidney, liver, heart) when used as induction therapy. - Treatment of severe aplastic anemia resistant to standard therapy. - Management of graft‑versus‑host disease (GVHD) following hematopoietic stem cell transplantation. - Adjunctive therapy in certain autoimmune disorders requiring profound T‑cell depletion, as determined by a specialist.

The safety profile of Grafalon reflects its mechanism of T‑cell depletion; side effects range from mild infusion‑related reactions to rare but serious complications.

Common: - Fever or chills during or shortly after infusion. - Nausea, vomiting, or abdominal discomfort. - Transient hypertension or hypotension. - Mild rash or urticaria at the infusion site. - Elevated liver enzymes or mild hepatic dysfunction.

Serious: - Severe allergic or anaphylactic reactions. - Cytokine release syndrome with high fever and hypotension. - Opportunistic infections such as cytomegalovirus or fungal infections. - Hemolytic anemia or thrombocytopenia. - Acute renal impairment or failure.

Because Grafalon profoundly suppresses the immune system, careful assessment and monitoring are required before, during, and after treatment.

- Verify patient’s infection status; active infections should be treated before administration. - Assess baseline liver and kidney function; dose adjustments may be needed for organ impairment. - Monitor complete blood counts regularly to detect cytopenias. - Evaluate for prior sensitization to rabbit proteins or known hypersensitivity. - Use caution in pregnant or breastfeeding individuals; benefits must outweigh potential risks. - Ensure appropriate vaccination status, avoiding live vaccines during therapy.

Grafalon may interact with other agents that affect immune function or hemodynamics; awareness of these interactions helps minimize adverse outcomes.

Avoid: - Concomitant use of other potent immunosuppressants (e.g., high‑dose steroids, calcineurin inhibitors) without close monitoring. - Live attenuated vaccines during and for several weeks after therapy. - Agents known to cause severe hypersensitivity reactions in rabbit‑derived products.

Use with caution: - Antimicrobial prophylaxis (antivirals, antifungals) to prevent opportunistic infections. - Drugs that influence renal clearance (e.g., aminoglycosides, NSAIDs) due to potential nephrotoxicity. - Medications that may exacerbate hypertension or hypotension during infusion (e.g., vasopressors). - Cytokine‑modulating agents that could amplify cytokine release syndrome.